id sid tid token lemma pos work_txjg7snw3bgwjg44gi5da2xsfm 1 1 untitled untitled JJ work_txjg7snw3bgwjg44gi5da2xsfm 1 2 JUNE JUNE NNP work_txjg7snw3bgwjg44gi5da2xsfm 1 3 2012 2012 CD work_txjg7snw3bgwjg44gi5da2xsfm 1 4 � � NNP work_txjg7snw3bgwjg44gi5da2xsfm 1 5 CANCER cancer JJ work_txjg7snw3bgwjg44gi5da2xsfm 1 6 DISCOVERY DISCOVERY NNP work_txjg7snw3bgwjg44gi5da2xsfm 1 7     _SP work_txjg7snw3bgwjg44gi5da2xsfm 1 8 | | CD work_txjg7snw3bgwjg44gi5da2xsfm 1 9     _SP work_txjg7snw3bgwjg44gi5da2xsfm 1 10 477 477 CD work_txjg7snw3bgwjg44gi5da2xsfm 1 11 NEWS NEWS NNP work_txjg7snw3bgwjg44gi5da2xsfm 1 12 IN in IN work_txjg7snw3bgwjg44gi5da2xsfm 1 13 BRIEF BRIEF NNP work_txjg7snw3bgwjg44gi5da2xsfm 1 14 100 100 CD work_txjg7snw3bgwjg44gi5da2xsfm 1 15 % % NN work_txjg7snw3bgwjg44gi5da2xsfm 1 16 . . . work_txjg7snw3bgwjg44gi5da2xsfm 2 1 Additionally additionally RB work_txjg7snw3bgwjg44gi5da2xsfm 2 2 , , , work_txjg7snw3bgwjg44gi5da2xsfm 2 3 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 2 4 pharmacoki- pharmacoki- XX work_txjg7snw3bgwjg44gi5da2xsfm 2 5 netics netic NNS work_txjg7snw3bgwjg44gi5da2xsfm 2 6 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 2 7 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 2 8 nanoparticle nanoparticle NN work_txjg7snw3bgwjg44gi5da2xsfm 2 9 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 2 10 encapsulated encapsulate VBN work_txjg7snw3bgwjg44gi5da2xsfm 2 11 drug drug NN work_txjg7snw3bgwjg44gi5da2xsfm 2 12 were be VBD work_txjg7snw3bgwjg44gi5da2xsfm 2 13 similar similar JJ work_txjg7snw3bgwjg44gi5da2xsfm 2 14 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 2 15 mice mouse NNS work_txjg7snw3bgwjg44gi5da2xsfm 2 16 , , , work_txjg7snw3bgwjg44gi5da2xsfm 2 17 rats rat NNS work_txjg7snw3bgwjg44gi5da2xsfm 2 18 , , , work_txjg7snw3bgwjg44gi5da2xsfm 2 19 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 2 20 monkeys monkey NNS work_txjg7snw3bgwjg44gi5da2xsfm 2 21 , , , work_txjg7snw3bgwjg44gi5da2xsfm 2 22 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 2 23 good good JJ work_txjg7snw3bgwjg44gi5da2xsfm 2 24 sign sign NN work_txjg7snw3bgwjg44gi5da2xsfm 2 25 that that IN work_txjg7snw3bgwjg44gi5da2xsfm 2 26 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 2 27 drug drug NN work_txjg7snw3bgwjg44gi5da2xsfm 2 28 will will MD work_txjg7snw3bgwjg44gi5da2xsfm 2 29 behave behave VB work_txjg7snw3bgwjg44gi5da2xsfm 2 30 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 2 31 same same JJ work_txjg7snw3bgwjg44gi5da2xsfm 2 32 way way NN work_txjg7snw3bgwjg44gi5da2xsfm 2 33 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 2 34 humans human NNS work_txjg7snw3bgwjg44gi5da2xsfm 2 35 . . . work_txjg7snw3bgwjg44gi5da2xsfm 3 1 At at IN work_txjg7snw3bgwjg44gi5da2xsfm 3 2 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 3 3 core core NN work_txjg7snw3bgwjg44gi5da2xsfm 3 4 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 3 5 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 3 6 drug drug NN work_txjg7snw3bgwjg44gi5da2xsfm 3 7 is be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 3 8 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 3 9 polymer polymer NN work_txjg7snw3bgwjg44gi5da2xsfm 3 10 sphere sphere NN work_txjg7snw3bgwjg44gi5da2xsfm 3 11 loaded load VBN work_txjg7snw3bgwjg44gi5da2xsfm 3 12 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 3 13 docetaxel docetaxel NNP work_txjg7snw3bgwjg44gi5da2xsfm 3 14 . . . work_txjg7snw3bgwjg44gi5da2xsfm 4 1 Jutting jut VBG work_txjg7snw3bgwjg44gi5da2xsfm 4 2 from from IN work_txjg7snw3bgwjg44gi5da2xsfm 4 3 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 4 4 surface surface NN work_txjg7snw3bgwjg44gi5da2xsfm 4 5 is be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 4 6 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 4 7 coating coating NN work_txjg7snw3bgwjg44gi5da2xsfm 4 8 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 4 9 poly- poly- NNP work_txjg7snw3bgwjg44gi5da2xsfm 4 10 ethylene ethylene NNP work_txjg7snw3bgwjg44gi5da2xsfm 4 11 glycol glycol NNP work_txjg7snw3bgwjg44gi5da2xsfm 4 12 molecules molecules NNP work_txjg7snw3bgwjg44gi5da2xsfm 4 13 , , , work_txjg7snw3bgwjg44gi5da2xsfm 4 14 which which WDT work_txjg7snw3bgwjg44gi5da2xsfm 4 15 serves serve VBZ work_txjg7snw3bgwjg44gi5da2xsfm 4 16 2 2 CD work_txjg7snw3bgwjg44gi5da2xsfm 4 17 purposes purpose NNS work_txjg7snw3bgwjg44gi5da2xsfm 4 18 . . . work_txjg7snw3bgwjg44gi5da2xsfm 5 1 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 5 2 polymer polymer NN work_txjg7snw3bgwjg44gi5da2xsfm 5 3 coating coating NN work_txjg7snw3bgwjg44gi5da2xsfm 5 4 helps help VBZ work_txjg7snw3bgwjg44gi5da2xsfm 5 5 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 5 6 drug drug NN work_txjg7snw3bgwjg44gi5da2xsfm 5 7 circulate circulate VB work_txjg7snw3bgwjg44gi5da2xsfm 5 8 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 5 9 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 5 10 bloodstream bloodstream NN work_txjg7snw3bgwjg44gi5da2xsfm 5 11 . . . work_txjg7snw3bgwjg44gi5da2xsfm 6 1 Also also RB work_txjg7snw3bgwjg44gi5da2xsfm 6 2 , , , work_txjg7snw3bgwjg44gi5da2xsfm 6 3 at at IN work_txjg7snw3bgwjg44gi5da2xsfm 6 4 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 6 5 tips tip NNS work_txjg7snw3bgwjg44gi5da2xsfm 6 6 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 6 7 some some DT work_txjg7snw3bgwjg44gi5da2xsfm 6 8 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 6 9 these these DT work_txjg7snw3bgwjg44gi5da2xsfm 6 10 poly- poly- NNS work_txjg7snw3bgwjg44gi5da2xsfm 6 11 ethylene ethylene NNP work_txjg7snw3bgwjg44gi5da2xsfm 6 12 glycol glycol NNP work_txjg7snw3bgwjg44gi5da2xsfm 6 13 molecules molecules NNPS work_txjg7snw3bgwjg44gi5da2xsfm 6 14 are be VBP work_txjg7snw3bgwjg44gi5da2xsfm 6 15 ligands ligand NNS work_txjg7snw3bgwjg44gi5da2xsfm 6 16 that that WDT work_txjg7snw3bgwjg44gi5da2xsfm 6 17 bind bind VBP work_txjg7snw3bgwjg44gi5da2xsfm 6 18 tightly tightly RB work_txjg7snw3bgwjg44gi5da2xsfm 6 19 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 6 20 specifi specifi VBD work_txjg7snw3bgwjg44gi5da2xsfm 6 21 cally cally RB work_txjg7snw3bgwjg44gi5da2xsfm 6 22 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 6 23 PSMA PSMA NNP work_txjg7snw3bgwjg44gi5da2xsfm 6 24 , , , work_txjg7snw3bgwjg44gi5da2xsfm 6 25 which which WDT work_txjg7snw3bgwjg44gi5da2xsfm 6 26 is be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 6 27 found find VBN work_txjg7snw3bgwjg44gi5da2xsfm 6 28 on on IN work_txjg7snw3bgwjg44gi5da2xsfm 6 29 prostate prostate NN work_txjg7snw3bgwjg44gi5da2xsfm 6 30 tumor tumor NN work_txjg7snw3bgwjg44gi5da2xsfm 6 31 cells cell NNS work_txjg7snw3bgwjg44gi5da2xsfm 6 32 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 6 33 on on IN work_txjg7snw3bgwjg44gi5da2xsfm 6 34 their -PRON- PRP$ work_txjg7snw3bgwjg44gi5da2xsfm 6 35 vasculature vasculature NN work_txjg7snw3bgwjg44gi5da2xsfm 6 36 . . . work_txjg7snw3bgwjg44gi5da2xsfm 7 1 BIND BIND NNP work_txjg7snw3bgwjg44gi5da2xsfm 7 2 Biosciences Biosciences NNP work_txjg7snw3bgwjg44gi5da2xsfm 7 3 combinatorially combinatorially RB work_txjg7snw3bgwjg44gi5da2xsfm 7 4 creates create VBZ work_txjg7snw3bgwjg44gi5da2xsfm 7 5 large large JJ work_txjg7snw3bgwjg44gi5da2xsfm 7 6 libraries library NNS work_txjg7snw3bgwjg44gi5da2xsfm 7 7 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 7 8 nanoparticle- nanoparticle- NNP work_txjg7snw3bgwjg44gi5da2xsfm 7 9 encapsulated encapsulate VBN work_txjg7snw3bgwjg44gi5da2xsfm 7 10 drugs drug NNS work_txjg7snw3bgwjg44gi5da2xsfm 7 11 , , , work_txjg7snw3bgwjg44gi5da2xsfm 7 12 each each DT work_txjg7snw3bgwjg44gi5da2xsfm 7 13 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 7 14 slightly slightly RB work_txjg7snw3bgwjg44gi5da2xsfm 7 15 different different JJ work_txjg7snw3bgwjg44gi5da2xsfm 7 16 properties property NNS work_txjg7snw3bgwjg44gi5da2xsfm 7 17 . . . work_txjg7snw3bgwjg44gi5da2xsfm 8 1 Researchers researcher NNS work_txjg7snw3bgwjg44gi5da2xsfm 8 2 then then RB work_txjg7snw3bgwjg44gi5da2xsfm 8 3 test test VBP work_txjg7snw3bgwjg44gi5da2xsfm 8 4 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 8 5 resulting result VBG work_txjg7snw3bgwjg44gi5da2xsfm 8 6 designs design NNS work_txjg7snw3bgwjg44gi5da2xsfm 8 7 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 8 8 rodents rodent NNS work_txjg7snw3bgwjg44gi5da2xsfm 8 9 , , , work_txjg7snw3bgwjg44gi5da2xsfm 8 10 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 8 11 iteratively iteratively RB work_txjg7snw3bgwjg44gi5da2xsfm 8 12 redesign redesign VB work_txjg7snw3bgwjg44gi5da2xsfm 8 13 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 8 14 ones one NNS work_txjg7snw3bgwjg44gi5da2xsfm 8 15 that that WDT work_txjg7snw3bgwjg44gi5da2xsfm 8 16 perform perform VBP work_txjg7snw3bgwjg44gi5da2xsfm 8 17 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 8 18 best good JJS work_txjg7snw3bgwjg44gi5da2xsfm 8 19 , , , work_txjg7snw3bgwjg44gi5da2xsfm 8 20 until until IN work_txjg7snw3bgwjg44gi5da2xsfm 8 21 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 8 22 drug drug NN work_txjg7snw3bgwjg44gi5da2xsfm 8 23 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 8 24 good good JJ work_txjg7snw3bgwjg44gi5da2xsfm 8 25 performance performance NN work_txjg7snw3bgwjg44gi5da2xsfm 8 26 emerges emerge NNS work_txjg7snw3bgwjg44gi5da2xsfm 8 27 . . . work_txjg7snw3bgwjg44gi5da2xsfm 9 1 With with IN work_txjg7snw3bgwjg44gi5da2xsfm 9 2 BIND-014 BIND-014 NNS work_txjg7snw3bgwjg44gi5da2xsfm 9 3 ’s ’s POS work_txjg7snw3bgwjg44gi5da2xsfm 9 4 basic basic JJ work_txjg7snw3bgwjg44gi5da2xsfm 9 5 nanoparti- nanoparti- NN work_txjg7snw3bgwjg44gi5da2xsfm 9 6 cle cle NN work_txjg7snw3bgwjg44gi5da2xsfm 9 7 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 9 8 encapsulated encapsulate VBN work_txjg7snw3bgwjg44gi5da2xsfm 9 9 delivery delivery NN work_txjg7snw3bgwjg44gi5da2xsfm 9 10 structure structure NN work_txjg7snw3bgwjg44gi5da2xsfm 9 11 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 9 12 place place NN work_txjg7snw3bgwjg44gi5da2xsfm 9 13 , , , work_txjg7snw3bgwjg44gi5da2xsfm 9 14 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 9 15 company company NN work_txjg7snw3bgwjg44gi5da2xsfm 9 16 expects expect VBZ work_txjg7snw3bgwjg44gi5da2xsfm 9 17 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 9 18 develop develop VB work_txjg7snw3bgwjg44gi5da2xsfm 9 19 targeted targeted JJ work_txjg7snw3bgwjg44gi5da2xsfm 9 20 therapies therapy NNS work_txjg7snw3bgwjg44gi5da2xsfm 9 21 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 9 22 other other JJ work_txjg7snw3bgwjg44gi5da2xsfm 9 23 diseases disease NNS work_txjg7snw3bgwjg44gi5da2xsfm 9 24 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 9 25 fewer few JJR work_txjg7snw3bgwjg44gi5da2xsfm 9 26 steps step NNS work_txjg7snw3bgwjg44gi5da2xsfm 9 27 , , , work_txjg7snw3bgwjg44gi5da2xsfm 9 28 by by IN work_txjg7snw3bgwjg44gi5da2xsfm 9 29 plugging plug VBG work_txjg7snw3bgwjg44gi5da2xsfm 9 30 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 9 31 different different JJ work_txjg7snw3bgwjg44gi5da2xsfm 9 32 drugs drug NNS work_txjg7snw3bgwjg44gi5da2xsfm 9 33 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 9 34 cell cell NN work_txjg7snw3bgwjg44gi5da2xsfm 9 35 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 9 36 targeting target VBG work_txjg7snw3bgwjg44gi5da2xsfm 9 37 molecules molecule NNS work_txjg7snw3bgwjg44gi5da2xsfm 9 38 . . . work_txjg7snw3bgwjg44gi5da2xsfm 10 1 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 10 2 potential potential JJ work_txjg7snw3bgwjg44gi5da2xsfm 10 3 benefi benefi JJ work_txjg7snw3bgwjg44gi5da2xsfm 10 4 ts ts NN work_txjg7snw3bgwjg44gi5da2xsfm 10 5 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 10 6 nano- nano- NNP work_txjg7snw3bgwjg44gi5da2xsfm 10 7 medicine medicine NN work_txjg7snw3bgwjg44gi5da2xsfm 10 8 “ " `` work_txjg7snw3bgwjg44gi5da2xsfm 10 9 are be VBP work_txjg7snw3bgwjg44gi5da2xsfm 10 10 vast vast JJ work_txjg7snw3bgwjg44gi5da2xsfm 10 11 but but CC work_txjg7snw3bgwjg44gi5da2xsfm 10 12 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 10 13 complexity complexity NN work_txjg7snw3bgwjg44gi5da2xsfm 10 14 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 10 15 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 10 16 system system NN work_txjg7snw3bgwjg44gi5da2xsfm 10 17 can can MD work_txjg7snw3bgwjg44gi5da2xsfm 10 18 be be VB work_txjg7snw3bgwjg44gi5da2xsfm 10 19 vast vast JJ work_txjg7snw3bgwjg44gi5da2xsfm 10 20 , , , work_txjg7snw3bgwjg44gi5da2xsfm 10 21 too too RB work_txjg7snw3bgwjg44gi5da2xsfm 10 22 , , , work_txjg7snw3bgwjg44gi5da2xsfm 10 23 ” " '' work_txjg7snw3bgwjg44gi5da2xsfm 10 24 says say VBZ work_txjg7snw3bgwjg44gi5da2xsfm 10 25 Sara Sara NNP work_txjg7snw3bgwjg44gi5da2xsfm 10 26 Hook Hook NNP work_txjg7snw3bgwjg44gi5da2xsfm 10 27 , , , work_txjg7snw3bgwjg44gi5da2xsfm 10 28 PhD phd NN work_txjg7snw3bgwjg44gi5da2xsfm 10 29 , , , work_txjg7snw3bgwjg44gi5da2xsfm 10 30 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 10 31 projects project NNS work_txjg7snw3bgwjg44gi5da2xsfm 10 32 manager manager NN work_txjg7snw3bgwjg44gi5da2xsfm 10 33 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 10 34 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 10 35 National National NNP work_txjg7snw3bgwjg44gi5da2xsfm 10 36 Cancer Cancer NNP work_txjg7snw3bgwjg44gi5da2xsfm 10 37 Institute Institute NNP work_txjg7snw3bgwjg44gi5da2xsfm 10 38 ’s ’s POS work_txjg7snw3bgwjg44gi5da2xsfm 10 39 offi offi NN work_txjg7snw3bgwjg44gi5da2xsfm 10 40 ce ce XX work_txjg7snw3bgwjg44gi5da2xsfm 10 41 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 10 42 Cancer Cancer NNP work_txjg7snw3bgwjg44gi5da2xsfm 10 43 Nanotechnology Nanotechnology NNP work_txjg7snw3bgwjg44gi5da2xsfm 10 44 Research Research NNP work_txjg7snw3bgwjg44gi5da2xsfm 10 45 . . . work_txjg7snw3bgwjg44gi5da2xsfm 11 1 There there EX work_txjg7snw3bgwjg44gi5da2xsfm 11 2 are be VBP work_txjg7snw3bgwjg44gi5da2xsfm 11 3 many many JJ work_txjg7snw3bgwjg44gi5da2xsfm 11 4 parameters parameter NNS work_txjg7snw3bgwjg44gi5da2xsfm 11 5 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 11 6 tune tune VB work_txjg7snw3bgwjg44gi5da2xsfm 11 7 — — : work_txjg7snw3bgwjg44gi5da2xsfm 11 8 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 11 9 example example NN work_txjg7snw3bgwjg44gi5da2xsfm 11 10 , , , work_txjg7snw3bgwjg44gi5da2xsfm 11 11 how how WRB work_txjg7snw3bgwjg44gi5da2xsfm 11 12 hydrophobic hydrophobic JJ work_txjg7snw3bgwjg44gi5da2xsfm 11 13 , , , work_txjg7snw3bgwjg44gi5da2xsfm 11 14 rigid rigid JJ work_txjg7snw3bgwjg44gi5da2xsfm 11 15 , , , work_txjg7snw3bgwjg44gi5da2xsfm 11 16 big big JJ work_txjg7snw3bgwjg44gi5da2xsfm 11 17 , , , work_txjg7snw3bgwjg44gi5da2xsfm 11 18 or or CC work_txjg7snw3bgwjg44gi5da2xsfm 11 19 small small JJ work_txjg7snw3bgwjg44gi5da2xsfm 11 20 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 11 21 particle particle NN work_txjg7snw3bgwjg44gi5da2xsfm 11 22 is be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 11 23 ; ; : work_txjg7snw3bgwjg44gi5da2xsfm 11 24 how how WRB work_txjg7snw3bgwjg44gi5da2xsfm 11 25 it -PRON- PRP work_txjg7snw3bgwjg44gi5da2xsfm 11 26 ’s ’ VBZ work_txjg7snw3bgwjg44gi5da2xsfm 11 27 attached attach VBN work_txjg7snw3bgwjg44gi5da2xsfm 11 28 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 11 29 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 11 30 drug drug NN work_txjg7snw3bgwjg44gi5da2xsfm 11 31 ; ; : work_txjg7snw3bgwjg44gi5da2xsfm 11 32 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 11 33 how how WRB work_txjg7snw3bgwjg44gi5da2xsfm 11 34 it -PRON- PRP work_txjg7snw3bgwjg44gi5da2xsfm 11 35 will will MD work_txjg7snw3bgwjg44gi5da2xsfm 11 36 bind bind VB work_txjg7snw3bgwjg44gi5da2xsfm 11 37 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 11 38 target target VB work_txjg7snw3bgwjg44gi5da2xsfm 11 39 cells cell NNS work_txjg7snw3bgwjg44gi5da2xsfm 11 40 . . . work_txjg7snw3bgwjg44gi5da2xsfm 12 1 It -PRON- PRP work_txjg7snw3bgwjg44gi5da2xsfm 12 2 ’s ’ VBZ work_txjg7snw3bgwjg44gi5da2xsfm 12 3 also also RB work_txjg7snw3bgwjg44gi5da2xsfm 12 4 diffi diffi JJ work_txjg7snw3bgwjg44gi5da2xsfm 12 5 cult cult NN work_txjg7snw3bgwjg44gi5da2xsfm 12 6 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 12 7 predict predict VB work_txjg7snw3bgwjg44gi5da2xsfm 12 8 how how WRB work_txjg7snw3bgwjg44gi5da2xsfm 12 9 changing change VBG work_txjg7snw3bgwjg44gi5da2xsfm 12 10 each each DT work_txjg7snw3bgwjg44gi5da2xsfm 12 11 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 12 12 these these DT work_txjg7snw3bgwjg44gi5da2xsfm 12 13 properties property NNS work_txjg7snw3bgwjg44gi5da2xsfm 12 14 will will MD work_txjg7snw3bgwjg44gi5da2xsfm 12 15 affect affect VB work_txjg7snw3bgwjg44gi5da2xsfm 12 16 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 12 17 nanoparticle nanoparticle NN work_txjg7snw3bgwjg44gi5da2xsfm 12 18 drug drug NN work_txjg7snw3bgwjg44gi5da2xsfm 12 19 ’s ’s POS work_txjg7snw3bgwjg44gi5da2xsfm 12 20 behavior behavior NN work_txjg7snw3bgwjg44gi5da2xsfm 12 21 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 12 22 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 12 23 body body NN work_txjg7snw3bgwjg44gi5da2xsfm 12 24 . . . work_txjg7snw3bgwjg44gi5da2xsfm 13 1 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 13 2 positive positive JJ work_txjg7snw3bgwjg44gi5da2xsfm 13 3 early early JJ work_txjg7snw3bgwjg44gi5da2xsfm 13 4 results result NNS work_txjg7snw3bgwjg44gi5da2xsfm 13 5 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 13 6 BIND- BIND- NNP work_txjg7snw3bgwjg44gi5da2xsfm 13 7 014 014 CD work_txjg7snw3bgwjg44gi5da2xsfm 13 8 demonstrate demonstrate VBP work_txjg7snw3bgwjg44gi5da2xsfm 13 9 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 13 10 promise promise NN work_txjg7snw3bgwjg44gi5da2xsfm 13 11 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 13 12 BIND BIND NNP work_txjg7snw3bgwjg44gi5da2xsfm 13 13 Bioscience Bioscience NNP work_txjg7snw3bgwjg44gi5da2xsfm 13 14 ’s ’s POS work_txjg7snw3bgwjg44gi5da2xsfm 13 15 approach approach NN work_txjg7snw3bgwjg44gi5da2xsfm 13 16 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 13 17 addressing address VBG work_txjg7snw3bgwjg44gi5da2xsfm 13 18 these these DT work_txjg7snw3bgwjg44gi5da2xsfm 13 19 challenges challenge NNS work_txjg7snw3bgwjg44gi5da2xsfm 13 20 , , , work_txjg7snw3bgwjg44gi5da2xsfm 13 21 Hook Hook NNP work_txjg7snw3bgwjg44gi5da2xsfm 13 22 says say VBZ work_txjg7snw3bgwjg44gi5da2xsfm 13 23 . . . work_txjg7snw3bgwjg44gi5da2xsfm 14 1 ■ ■ NFP work_txjg7snw3bgwjg44gi5da2xsfm 14 2 BEAUTY BEAUTY NNP work_txjg7snw3bgwjg44gi5da2xsfm 14 3 Combines Combines NNP work_txjg7snw3bgwjg44gi5da2xsfm 14 4 Sequencing Sequencing NNP work_txjg7snw3bgwjg44gi5da2xsfm 14 5 , , , work_txjg7snw3bgwjg44gi5da2xsfm 14 6 Avatars Avatars NNP work_txjg7snw3bgwjg44gi5da2xsfm 14 7 Researchers Researchers NNPS work_txjg7snw3bgwjg44gi5da2xsfm 14 8 at at IN work_txjg7snw3bgwjg44gi5da2xsfm 14 9 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 14 10 Mayo Mayo NNP work_txjg7snw3bgwjg44gi5da2xsfm 14 11 Clinic Clinic NNP work_txjg7snw3bgwjg44gi5da2xsfm 14 12 Cancer Cancer NNP work_txjg7snw3bgwjg44gi5da2xsfm 14 13 Center Center NNP work_txjg7snw3bgwjg44gi5da2xsfm 14 14 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 14 15 Rochester Rochester NNP work_txjg7snw3bgwjg44gi5da2xsfm 14 16 , , , work_txjg7snw3bgwjg44gi5da2xsfm 14 17 MN MN NNP work_txjg7snw3bgwjg44gi5da2xsfm 14 18 , , , work_txjg7snw3bgwjg44gi5da2xsfm 14 19 have have VBP work_txjg7snw3bgwjg44gi5da2xsfm 14 20 launched launch VBN work_txjg7snw3bgwjg44gi5da2xsfm 14 21 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 14 22 clinical clinical JJ work_txjg7snw3bgwjg44gi5da2xsfm 14 23 study study NN work_txjg7snw3bgwjg44gi5da2xsfm 14 24 that that WDT work_txjg7snw3bgwjg44gi5da2xsfm 14 25 pairs pair VBZ work_txjg7snw3bgwjg44gi5da2xsfm 14 26 whole whole RB work_txjg7snw3bgwjg44gi5da2xsfm 14 27 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 14 28 genome genome RB work_txjg7snw3bgwjg44gi5da2xsfm 14 29 sequencing sequencing NN work_txjg7snw3bgwjg44gi5da2xsfm 14 30 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 14 31 mouse mouse NN work_txjg7snw3bgwjg44gi5da2xsfm 14 32 “ " `` work_txjg7snw3bgwjg44gi5da2xsfm 14 33 avatars avatars FW work_txjg7snw3bgwjg44gi5da2xsfm 14 34 ” " '' work_txjg7snw3bgwjg44gi5da2xsfm 14 35 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 14 36 an an DT work_txjg7snw3bgwjg44gi5da2xsfm 14 37 effort effort NN work_txjg7snw3bgwjg44gi5da2xsfm 14 38 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 14 39 bring bring VB work_txjg7snw3bgwjg44gi5da2xsfm 14 40 clinical clinical JJ work_txjg7snw3bgwjg44gi5da2xsfm 14 41 care care NN work_txjg7snw3bgwjg44gi5da2xsfm 14 42 closer close RBR work_txjg7snw3bgwjg44gi5da2xsfm 14 43 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 14 44 individualized individualized JJ work_txjg7snw3bgwjg44gi5da2xsfm 14 45 treatment treatment NN work_txjg7snw3bgwjg44gi5da2xsfm 14 46 . . . work_txjg7snw3bgwjg44gi5da2xsfm 15 1 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 15 2 Breast Breast NNP work_txjg7snw3bgwjg44gi5da2xsfm 15 3 Cancer Cancer NNP work_txjg7snw3bgwjg44gi5da2xsfm 15 4 Genome Genome NNP work_txjg7snw3bgwjg44gi5da2xsfm 15 5 Guided guide VBN work_txjg7snw3bgwjg44gi5da2xsfm 15 6 Therapy therapy NN work_txjg7snw3bgwjg44gi5da2xsfm 15 7 ( ( -LRB- work_txjg7snw3bgwjg44gi5da2xsfm 15 8 BEAUTY BEAUTY NNP work_txjg7snw3bgwjg44gi5da2xsfm 15 9 ) ) -RRB- work_txjg7snw3bgwjg44gi5da2xsfm 15 10 study study NN work_txjg7snw3bgwjg44gi5da2xsfm 15 11 involves involve VBZ work_txjg7snw3bgwjg44gi5da2xsfm 15 12 200 200 CD work_txjg7snw3bgwjg44gi5da2xsfm 15 13 women woman NNS work_txjg7snw3bgwjg44gi5da2xsfm 15 14 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 15 15 nonmetastatic nonmetastatic JJ work_txjg7snw3bgwjg44gi5da2xsfm 15 16 breast breast NN work_txjg7snw3bgwjg44gi5da2xsfm 15 17 cancer cancer NN work_txjg7snw3bgwjg44gi5da2xsfm 15 18 receiving receive VBG work_txjg7snw3bgwjg44gi5da2xsfm 15 19 chemotherapy chemotherapy NN work_txjg7snw3bgwjg44gi5da2xsfm 15 20 prior prior RB work_txjg7snw3bgwjg44gi5da2xsfm 15 21 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 15 22 surgery surgery NN work_txjg7snw3bgwjg44gi5da2xsfm 15 23 . . . work_txjg7snw3bgwjg44gi5da2xsfm 16 1 Before before IN work_txjg7snw3bgwjg44gi5da2xsfm 16 2 starting start VBG work_txjg7snw3bgwjg44gi5da2xsfm 16 3 chemotherapy chemotherapy NN work_txjg7snw3bgwjg44gi5da2xsfm 16 4 , , , work_txjg7snw3bgwjg44gi5da2xsfm 16 5 investigators investigator NNS work_txjg7snw3bgwjg44gi5da2xsfm 16 6 will will MD work_txjg7snw3bgwjg44gi5da2xsfm 16 7 sequence sequence VB work_txjg7snw3bgwjg44gi5da2xsfm 16 8 both both CC work_txjg7snw3bgwjg44gi5da2xsfm 16 9 cancer- cancer- NN work_txjg7snw3bgwjg44gi5da2xsfm 16 10 ous ous JJ work_txjg7snw3bgwjg44gi5da2xsfm 16 11 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 16 12 healthy healthy JJ work_txjg7snw3bgwjg44gi5da2xsfm 16 13 cells cell NNS work_txjg7snw3bgwjg44gi5da2xsfm 16 14 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 16 15 identify identify VB work_txjg7snw3bgwjg44gi5da2xsfm 16 16 tumor- tumor- NN work_txjg7snw3bgwjg44gi5da2xsfm 16 17 specifi specifi NN work_txjg7snw3bgwjg44gi5da2xsfm 16 18 c c NNP work_txjg7snw3bgwjg44gi5da2xsfm 16 19 changes change VBZ work_txjg7snw3bgwjg44gi5da2xsfm 16 20 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 16 21 each each DT work_txjg7snw3bgwjg44gi5da2xsfm 16 22 patient patient NN work_txjg7snw3bgwjg44gi5da2xsfm 16 23 . . . work_txjg7snw3bgwjg44gi5da2xsfm 17 1 For for IN work_txjg7snw3bgwjg44gi5da2xsfm 17 2 patients patient NNS work_txjg7snw3bgwjg44gi5da2xsfm 17 3 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 17 4 disease disease NN work_txjg7snw3bgwjg44gi5da2xsfm 17 5 that that WDT work_txjg7snw3bgwjg44gi5da2xsfm 17 6 is be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 17 7 resistant resistant JJ work_txjg7snw3bgwjg44gi5da2xsfm 17 8 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 17 9 standard standard JJ work_txjg7snw3bgwjg44gi5da2xsfm 17 10 chemotherapy chemotherapy NN work_txjg7snw3bgwjg44gi5da2xsfm 17 11 , , , work_txjg7snw3bgwjg44gi5da2xsfm 17 12 tumor tumor NN work_txjg7snw3bgwjg44gi5da2xsfm 17 13 cells cell NNS work_txjg7snw3bgwjg44gi5da2xsfm 17 14 will will MD work_txjg7snw3bgwjg44gi5da2xsfm 17 15 also also RB work_txjg7snw3bgwjg44gi5da2xsfm 17 16 be be VB work_txjg7snw3bgwjg44gi5da2xsfm 17 17 sequenced sequence VBN work_txjg7snw3bgwjg44gi5da2xsfm 17 18 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 17 19 determine determine VB work_txjg7snw3bgwjg44gi5da2xsfm 17 20 which which WDT work_txjg7snw3bgwjg44gi5da2xsfm 17 21 mutations mutation NNS work_txjg7snw3bgwjg44gi5da2xsfm 17 22 helped help VBD work_txjg7snw3bgwjg44gi5da2xsfm 17 23 them -PRON- PRP work_txjg7snw3bgwjg44gi5da2xsfm 17 24 survive survive VB work_txjg7snw3bgwjg44gi5da2xsfm 17 25 . . . work_txjg7snw3bgwjg44gi5da2xsfm 18 1 Study study NN work_txjg7snw3bgwjg44gi5da2xsfm 18 2 co co NNS work_txjg7snw3bgwjg44gi5da2xsfm 18 3 - - NNS work_txjg7snw3bgwjg44gi5da2xsfm 18 4 leaders leader NNS work_txjg7snw3bgwjg44gi5da2xsfm 18 5 , , , work_txjg7snw3bgwjg44gi5da2xsfm 18 6 Judy Judy NNP work_txjg7snw3bgwjg44gi5da2xsfm 18 7 Boughey Boughey NNP work_txjg7snw3bgwjg44gi5da2xsfm 18 8 , , , work_txjg7snw3bgwjg44gi5da2xsfm 18 9 MD MD NNP work_txjg7snw3bgwjg44gi5da2xsfm 18 10 , , , work_txjg7snw3bgwjg44gi5da2xsfm 18 11 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 18 12 breast breast NN work_txjg7snw3bgwjg44gi5da2xsfm 18 13 surgeon surgeon NN work_txjg7snw3bgwjg44gi5da2xsfm 18 14 , , , work_txjg7snw3bgwjg44gi5da2xsfm 18 15 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 18 16 Matthew Matthew NNP work_txjg7snw3bgwjg44gi5da2xsfm 18 17 Goetz Goetz NNP work_txjg7snw3bgwjg44gi5da2xsfm 18 18 , , , work_txjg7snw3bgwjg44gi5da2xsfm 18 19 MD MD NNP work_txjg7snw3bgwjg44gi5da2xsfm 18 20 , , , work_txjg7snw3bgwjg44gi5da2xsfm 18 21 an an DT work_txjg7snw3bgwjg44gi5da2xsfm 18 22 oncologist oncologist NN work_txjg7snw3bgwjg44gi5da2xsfm 18 23 , , , work_txjg7snw3bgwjg44gi5da2xsfm 18 24 expect expect VB work_txjg7snw3bgwjg44gi5da2xsfm 18 25 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 18 26 fi fi VB work_txjg7snw3bgwjg44gi5da2xsfm 18 27 nd nd NNP work_txjg7snw3bgwjg44gi5da2xsfm 18 28 known know VBN work_txjg7snw3bgwjg44gi5da2xsfm 18 29 mutations mutation NNS work_txjg7snw3bgwjg44gi5da2xsfm 18 30 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 18 31 which which WDT work_txjg7snw3bgwjg44gi5da2xsfm 18 32 drugs drug NNS work_txjg7snw3bgwjg44gi5da2xsfm 18 33 already already RB work_txjg7snw3bgwjg44gi5da2xsfm 18 34 exist exist VBP work_txjg7snw3bgwjg44gi5da2xsfm 18 35 as as RB work_txjg7snw3bgwjg44gi5da2xsfm 18 36 well well RB work_txjg7snw3bgwjg44gi5da2xsfm 18 37 as as IN work_txjg7snw3bgwjg44gi5da2xsfm 18 38 targets target NNS work_txjg7snw3bgwjg44gi5da2xsfm 18 39 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 18 40 new new JJ work_txjg7snw3bgwjg44gi5da2xsfm 18 41 drugs drug NNS work_txjg7snw3bgwjg44gi5da2xsfm 18 42 . . . work_txjg7snw3bgwjg44gi5da2xsfm 19 1 In in IN work_txjg7snw3bgwjg44gi5da2xsfm 19 2 parallel parallel NN work_txjg7snw3bgwjg44gi5da2xsfm 19 3 , , , work_txjg7snw3bgwjg44gi5da2xsfm 19 4 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 19 5 investigators investigator NNS work_txjg7snw3bgwjg44gi5da2xsfm 19 6 will will MD work_txjg7snw3bgwjg44gi5da2xsfm 19 7 implant implant VB work_txjg7snw3bgwjg44gi5da2xsfm 19 8 tumor tumor NN work_txjg7snw3bgwjg44gi5da2xsfm 19 9 samples sample NNS work_txjg7snw3bgwjg44gi5da2xsfm 19 10 taken take VBN work_txjg7snw3bgwjg44gi5da2xsfm 19 11 before before RB work_txjg7snw3bgwjg44gi5da2xsfm 19 12 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 19 13 after after IN work_txjg7snw3bgwjg44gi5da2xsfm 19 14 chemotherapy chemotherapy NN work_txjg7snw3bgwjg44gi5da2xsfm 19 15 into into IN work_txjg7snw3bgwjg44gi5da2xsfm 19 16 2 2 CD work_txjg7snw3bgwjg44gi5da2xsfm 19 17 immuno- immuno- NN work_txjg7snw3bgwjg44gi5da2xsfm 19 18 suppressed suppress VBN work_txjg7snw3bgwjg44gi5da2xsfm 19 19 mice mouse NNS work_txjg7snw3bgwjg44gi5da2xsfm 19 20 , , , work_txjg7snw3bgwjg44gi5da2xsfm 19 21 creating create VBG work_txjg7snw3bgwjg44gi5da2xsfm 19 22 individualized individualize VBN work_txjg7snw3bgwjg44gi5da2xsfm 19 23 mouse mouse NN work_txjg7snw3bgwjg44gi5da2xsfm 19 24 avatars avatar NNS work_txjg7snw3bgwjg44gi5da2xsfm 19 25 , , , work_txjg7snw3bgwjg44gi5da2xsfm 19 26 or or CC work_txjg7snw3bgwjg44gi5da2xsfm 19 27 stand stand NN work_txjg7snw3bgwjg44gi5da2xsfm 19 28 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 19 29 ins in NNS work_txjg7snw3bgwjg44gi5da2xsfm 19 30 , , , work_txjg7snw3bgwjg44gi5da2xsfm 19 31 that that WDT work_txjg7snw3bgwjg44gi5da2xsfm 19 32 repre- repre- NN work_txjg7snw3bgwjg44gi5da2xsfm 19 33 sent send VBD work_txjg7snw3bgwjg44gi5da2xsfm 19 34 each each DT work_txjg7snw3bgwjg44gi5da2xsfm 19 35 patient patient NN work_txjg7snw3bgwjg44gi5da2xsfm 19 36 . . . work_txjg7snw3bgwjg44gi5da2xsfm 20 1 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 20 2 avatars avatar NNS work_txjg7snw3bgwjg44gi5da2xsfm 20 3 immortal- immortal- NN work_txjg7snw3bgwjg44gi5da2xsfm 20 4 ize ize VB work_txjg7snw3bgwjg44gi5da2xsfm 20 5 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 20 6 tumors tumor NNS work_txjg7snw3bgwjg44gi5da2xsfm 20 7 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 20 8 live live JJ work_txjg7snw3bgwjg44gi5da2xsfm 20 9 animals animal NNS work_txjg7snw3bgwjg44gi5da2xsfm 20 10 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 20 11 factor factor NN work_txjg7snw3bgwjg44gi5da2xsfm 20 12 in in RP work_txjg7snw3bgwjg44gi5da2xsfm 20 13 complexities complexity NNS work_txjg7snw3bgwjg44gi5da2xsfm 20 14 such such JJ work_txjg7snw3bgwjg44gi5da2xsfm 20 15 as as IN work_txjg7snw3bgwjg44gi5da2xsfm 20 16 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 20 17 role role NN work_txjg7snw3bgwjg44gi5da2xsfm 20 18 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 20 19 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 20 20 microenvironment microenvironment NN work_txjg7snw3bgwjg44gi5da2xsfm 20 21 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 20 22 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 20 23 progression progression NN work_txjg7snw3bgwjg44gi5da2xsfm 20 24 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 20 25 metastatic metastatic JJ work_txjg7snw3bgwjg44gi5da2xsfm 20 26 potential potential NN work_txjg7snw3bgwjg44gi5da2xsfm 20 27 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 20 28 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 20 29 cancer cancer NN work_txjg7snw3bgwjg44gi5da2xsfm 20 30 cell cell NN work_txjg7snw3bgwjg44gi5da2xsfm 20 31 . . . work_txjg7snw3bgwjg44gi5da2xsfm 21 1 For for IN work_txjg7snw3bgwjg44gi5da2xsfm 21 2 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 21 3 patient patient NN work_txjg7snw3bgwjg44gi5da2xsfm 21 4 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 21 5 recurring recur VBG work_txjg7snw3bgwjg44gi5da2xsfm 21 6 disease disease NN work_txjg7snw3bgwjg44gi5da2xsfm 21 7 , , , work_txjg7snw3bgwjg44gi5da2xsfm 21 8 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 21 9 researchers researcher NNS work_txjg7snw3bgwjg44gi5da2xsfm 21 10 plan plan VBP work_txjg7snw3bgwjg44gi5da2xsfm 21 11 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 21 12 increase increase VB work_txjg7snw3bgwjg44gi5da2xsfm 21 13 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 21 14 number number NN work_txjg7snw3bgwjg44gi5da2xsfm 21 15 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 21 16 avatars avatar NNS work_txjg7snw3bgwjg44gi5da2xsfm 21 17 so so IN work_txjg7snw3bgwjg44gi5da2xsfm 21 18 that that IN work_txjg7snw3bgwjg44gi5da2xsfm 21 19 they -PRON- PRP work_txjg7snw3bgwjg44gi5da2xsfm 21 20 can can MD work_txjg7snw3bgwjg44gi5da2xsfm 21 21 test test VB work_txjg7snw3bgwjg44gi5da2xsfm 21 22 multiple multiple JJ work_txjg7snw3bgwjg44gi5da2xsfm 21 23 drug drug NN work_txjg7snw3bgwjg44gi5da2xsfm 21 24 candidates candidate NNS work_txjg7snw3bgwjg44gi5da2xsfm 21 25 at at IN work_txjg7snw3bgwjg44gi5da2xsfm 21 26 once once RB work_txjg7snw3bgwjg44gi5da2xsfm 21 27 . . . work_txjg7snw3bgwjg44gi5da2xsfm 22 1 Further further RB work_txjg7snw3bgwjg44gi5da2xsfm 22 2 , , , work_txjg7snw3bgwjg44gi5da2xsfm 22 3 if if IN work_txjg7snw3bgwjg44gi5da2xsfm 22 4 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 22 5 new new JJ work_txjg7snw3bgwjg44gi5da2xsfm 22 6 drug drug NN work_txjg7snw3bgwjg44gi5da2xsfm 22 7 emerges emerge NNS work_txjg7snw3bgwjg44gi5da2xsfm 22 8 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 22 9 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 22 10 future future NN work_txjg7snw3bgwjg44gi5da2xsfm 22 11 , , , work_txjg7snw3bgwjg44gi5da2xsfm 22 12 it -PRON- PRP work_txjg7snw3bgwjg44gi5da2xsfm 22 13 can can MD work_txjg7snw3bgwjg44gi5da2xsfm 22 14 also also RB work_txjg7snw3bgwjg44gi5da2xsfm 22 15 be be VB work_txjg7snw3bgwjg44gi5da2xsfm 22 16 tested test VBN work_txjg7snw3bgwjg44gi5da2xsfm 22 17 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 22 18 that that DT work_txjg7snw3bgwjg44gi5da2xsfm 22 19 patient patient NN work_txjg7snw3bgwjg44gi5da2xsfm 22 20 ’s ’s POS work_txjg7snw3bgwjg44gi5da2xsfm 22 21 avatars avatar NNS work_txjg7snw3bgwjg44gi5da2xsfm 22 22 . . . work_txjg7snw3bgwjg44gi5da2xsfm 23 1 “ " `` work_txjg7snw3bgwjg44gi5da2xsfm 23 2 We -PRON- PRP work_txjg7snw3bgwjg44gi5da2xsfm 23 3 ’re be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 23 4 not not RB work_txjg7snw3bgwjg44gi5da2xsfm 23 5 ready ready JJ work_txjg7snw3bgwjg44gi5da2xsfm 23 6 yet yet RB work_txjg7snw3bgwjg44gi5da2xsfm 23 7 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 23 8 introduce introduce VB work_txjg7snw3bgwjg44gi5da2xsfm 23 9 tumor tumor NN work_txjg7snw3bgwjg44gi5da2xsfm 23 10 genome genome NNP work_txjg7snw3bgwjg44gi5da2xsfm 23 11 sequence sequence NN work_txjg7snw3bgwjg44gi5da2xsfm 23 12 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 23 13 based base VBN work_txjg7snw3bgwjg44gi5da2xsfm 23 14 selec- selec- NN work_txjg7snw3bgwjg44gi5da2xsfm 23 15 tion tion NN work_txjg7snw3bgwjg44gi5da2xsfm 23 16 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 23 17 drugs drug NNS work_txjg7snw3bgwjg44gi5da2xsfm 23 18 into into IN work_txjg7snw3bgwjg44gi5da2xsfm 23 19 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 23 20 neoadjuvant neoadjuvant JJ work_txjg7snw3bgwjg44gi5da2xsfm 23 21 setting setting NN work_txjg7snw3bgwjg44gi5da2xsfm 23 22 , , , work_txjg7snw3bgwjg44gi5da2xsfm 23 23 but but CC work_txjg7snw3bgwjg44gi5da2xsfm 23 24 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 23 25 avatars avatar NNS work_txjg7snw3bgwjg44gi5da2xsfm 23 26 give give VBP work_txjg7snw3bgwjg44gi5da2xsfm 23 27 us -PRON- PRP work_txjg7snw3bgwjg44gi5da2xsfm 23 28 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 23 29 way way NN work_txjg7snw3bgwjg44gi5da2xsfm 23 30 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 23 31 prospectively prospectively RB work_txjg7snw3bgwjg44gi5da2xsfm 23 32 study study VB work_txjg7snw3bgwjg44gi5da2xsfm 23 33 these these DT work_txjg7snw3bgwjg44gi5da2xsfm 23 34 patients patient NNS work_txjg7snw3bgwjg44gi5da2xsfm 23 35 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 23 36 rationally rationally RB work_txjg7snw3bgwjg44gi5da2xsfm 23 37 move move VB work_txjg7snw3bgwjg44gi5da2xsfm 23 38 towards towards IN work_txjg7snw3bgwjg44gi5da2xsfm 23 39 more more RBR work_txjg7snw3bgwjg44gi5da2xsfm 23 40 individualized individualized JJ work_txjg7snw3bgwjg44gi5da2xsfm 23 41 therapy therapy NN work_txjg7snw3bgwjg44gi5da2xsfm 23 42 , , , work_txjg7snw3bgwjg44gi5da2xsfm 23 43 ” " '' work_txjg7snw3bgwjg44gi5da2xsfm 23 44 says say VBZ work_txjg7snw3bgwjg44gi5da2xsfm 23 45 Goetz Goetz NNP work_txjg7snw3bgwjg44gi5da2xsfm 23 46 . . . work_txjg7snw3bgwjg44gi5da2xsfm 24 1 ■ ■ NFP work_txjg7snw3bgwjg44gi5da2xsfm 24 2 For for IN work_txjg7snw3bgwjg44gi5da2xsfm 24 3 more more JJR work_txjg7snw3bgwjg44gi5da2xsfm 24 4 news news NN work_txjg7snw3bgwjg44gi5da2xsfm 24 5 on on IN work_txjg7snw3bgwjg44gi5da2xsfm 24 6 cancer cancer NN work_txjg7snw3bgwjg44gi5da2xsfm 24 7 research research NN work_txjg7snw3bgwjg44gi5da2xsfm 24 8 , , , work_txjg7snw3bgwjg44gi5da2xsfm 24 9 visit visit VB work_txjg7snw3bgwjg44gi5da2xsfm 24 10 Cancer Cancer NNP work_txjg7snw3bgwjg44gi5da2xsfm 24 11 Discovery Discovery NNP work_txjg7snw3bgwjg44gi5da2xsfm 24 12 online online RB work_txjg7snw3bgwjg44gi5da2xsfm 24 13 at at IN work_txjg7snw3bgwjg44gi5da2xsfm 24 14 http://CDnews.aacrjournals.org http://CDnews.aacrjournals.org NNP work_txjg7snw3bgwjg44gi5da2xsfm 24 15 . . . work_txjg7snw3bgwjg44gi5da2xsfm 25 1 • • NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 2     _SP work_txjg7snw3bgwjg44gi5da2xsfm 25 3 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 25 4 NIH NIH NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 5 extramural extramural JJ work_txjg7snw3bgwjg44gi5da2xsfm 25 6 budget budget NN work_txjg7snw3bgwjg44gi5da2xsfm 25 7 will will MD work_txjg7snw3bgwjg44gi5da2xsfm 25 8 drop drop VB work_txjg7snw3bgwjg44gi5da2xsfm 25 9 by by IN work_txjg7snw3bgwjg44gi5da2xsfm 25 10 11.1 11.1 CD work_txjg7snw3bgwjg44gi5da2xsfm 25 11 % % NN work_txjg7snw3bgwjg44gi5da2xsfm 25 12 ( ( -LRB- work_txjg7snw3bgwjg44gi5da2xsfm 25 13 $ $ $ work_txjg7snw3bgwjg44gi5da2xsfm 25 14 2.8 2.8 CD work_txjg7snw3bgwjg44gi5da2xsfm 25 15 billion billion CD work_txjg7snw3bgwjg44gi5da2xsfm 25 16 ) ) -RRB- work_txjg7snw3bgwjg44gi5da2xsfm 25 17 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 25 18 January January NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 19 2013 2013 CD work_txjg7snw3bgwjg44gi5da2xsfm 25 20 if if IN work_txjg7snw3bgwjg44gi5da2xsfm 25 21 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 25 22 Budget Budget NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 23 Control Control NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 24 Act Act NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 25 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 25 26 2011 2011 CD work_txjg7snw3bgwjg44gi5da2xsfm 25 27 ’s ’s NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 28 “ " `` work_txjg7snw3bgwjg44gi5da2xsfm 25 29 se- se- NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 30 questration questration NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 31 ” " '' work_txjg7snw3bgwjg44gi5da2xsfm 25 32 mechanism mechanism NN work_txjg7snw3bgwjg44gi5da2xsfm 25 33 kicks kick VBZ work_txjg7snw3bgwjg44gi5da2xsfm 25 34 in in RP work_txjg7snw3bgwjg44gi5da2xsfm 25 35 , , , work_txjg7snw3bgwjg44gi5da2xsfm 25 36 sug- sug- NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 37 gested geste VBD work_txjg7snw3bgwjg44gi5da2xsfm 25 38 an an DT work_txjg7snw3bgwjg44gi5da2xsfm 25 39 analysis analysis NN work_txjg7snw3bgwjg44gi5da2xsfm 25 40 from from IN work_txjg7snw3bgwjg44gi5da2xsfm 25 41 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 25 42 Federation Federation NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 43 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 25 44 American American NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 45 Societies Societies NNPS work_txjg7snw3bgwjg44gi5da2xsfm 25 46 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 25 47 Experimental Experimental NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 48 Biology Biology NNP work_txjg7snw3bgwjg44gi5da2xsfm 25 49 . . . work_txjg7snw3bgwjg44gi5da2xsfm 26 1 • • NNP work_txjg7snw3bgwjg44gi5da2xsfm 26 2     _SP work_txjg7snw3bgwjg44gi5da2xsfm 26 3 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 26 4 U.S. U.S. NNP work_txjg7snw3bgwjg44gi5da2xsfm 26 5 Food Food NNP work_txjg7snw3bgwjg44gi5da2xsfm 26 6 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 26 7 Drug Drug NNP work_txjg7snw3bgwjg44gi5da2xsfm 26 8 Administration Administration NNP work_txjg7snw3bgwjg44gi5da2xsfm 26 9 ( ( -LRB- work_txjg7snw3bgwjg44gi5da2xsfm 26 10 FDA FDA NNP work_txjg7snw3bgwjg44gi5da2xsfm 26 11 ) ) -RRB- work_txjg7snw3bgwjg44gi5da2xsfm 26 12 approved approve VBD work_txjg7snw3bgwjg44gi5da2xsfm 26 13 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 26 14 antiangiogenesis antiangiogenesis NN work_txjg7snw3bgwjg44gi5da2xsfm 26 15 agent agent NN work_txjg7snw3bgwjg44gi5da2xsfm 26 16 pazopanib pazopanib NN work_txjg7snw3bgwjg44gi5da2xsfm 26 17 ( ( -LRB- work_txjg7snw3bgwjg44gi5da2xsfm 26 18 Votrient Votrient NNP work_txjg7snw3bgwjg44gi5da2xsfm 26 19 ; ; : work_txjg7snw3bgwjg44gi5da2xsfm 26 20 GlaxoSmith- GlaxoSmith- NNP work_txjg7snw3bgwjg44gi5da2xsfm 26 21 Kline Kline NNP work_txjg7snw3bgwjg44gi5da2xsfm 26 22 ) ) -RRB- work_txjg7snw3bgwjg44gi5da2xsfm 26 23 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 26 24 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 26 25 treatment treatment NN work_txjg7snw3bgwjg44gi5da2xsfm 26 26 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 26 27 patients patient NNS work_txjg7snw3bgwjg44gi5da2xsfm 26 28 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 26 29 advanced advanced JJ work_txjg7snw3bgwjg44gi5da2xsfm 26 30 soft soft JJ work_txjg7snw3bgwjg44gi5da2xsfm 26 31 tissue tissue NN work_txjg7snw3bgwjg44gi5da2xsfm 26 32 sarcoma sarcoma NN work_txjg7snw3bgwjg44gi5da2xsfm 26 33 . . . work_txjg7snw3bgwjg44gi5da2xsfm 27 1 “ " `` work_txjg7snw3bgwjg44gi5da2xsfm 27 2 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 27 3 approval approval NN work_txjg7snw3bgwjg44gi5da2xsfm 27 4 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 27 5 pazopanib pazopanib NN work_txjg7snw3bgwjg44gi5da2xsfm 27 6 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 27 7 this this DT work_txjg7snw3bgwjg44gi5da2xsfm 27 8 general general JJ work_txjg7snw3bgwjg44gi5da2xsfm 27 9 class class NN work_txjg7snw3bgwjg44gi5da2xsfm 27 10 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 27 11 tumors tumor NNS work_txjg7snw3bgwjg44gi5da2xsfm 27 12 is be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 27 13 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 27 14 first first JJ work_txjg7snw3bgwjg44gi5da2xsfm 27 15 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 27 16 decades decade NNS work_txjg7snw3bgwjg44gi5da2xsfm 27 17 , , , work_txjg7snw3bgwjg44gi5da2xsfm 27 18 ” " '' work_txjg7snw3bgwjg44gi5da2xsfm 27 19 noted note VBD work_txjg7snw3bgwjg44gi5da2xsfm 27 20 Dr. Dr. NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 21 Richard Richard NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 22 Pazdur Pazdur NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 23 , , , work_txjg7snw3bgwjg44gi5da2xsfm 27 24 director director NN work_txjg7snw3bgwjg44gi5da2xsfm 27 25 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 27 26 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 27 27 Office Office NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 28 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 27 29 Hematology Hematology NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 30 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 27 31 Oncology Oncology NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 32 Products Products NNPS work_txjg7snw3bgwjg44gi5da2xsfm 27 33 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 27 34 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 27 35 FDA FDA NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 36 ’s ’s NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 37 Center Center NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 38 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 27 39 Drug Drug NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 40 Evaluation Evaluation NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 41 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 27 42 Research Research NNP work_txjg7snw3bgwjg44gi5da2xsfm 27 43 . . . work_txjg7snw3bgwjg44gi5da2xsfm 28 1 • • NNP work_txjg7snw3bgwjg44gi5da2xsfm 28 2     _SP work_txjg7snw3bgwjg44gi5da2xsfm 28 3 Women woman NNS work_txjg7snw3bgwjg44gi5da2xsfm 28 4 have have VBP work_txjg7snw3bgwjg44gi5da2xsfm 28 5 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 28 6 30 30 CD work_txjg7snw3bgwjg44gi5da2xsfm 28 7 % % NN work_txjg7snw3bgwjg44gi5da2xsfm 28 8 relative relative JJ work_txjg7snw3bgwjg44gi5da2xsfm 28 9 advantage advantage NN work_txjg7snw3bgwjg44gi5da2xsfm 28 10 over over IN work_txjg7snw3bgwjg44gi5da2xsfm 28 11 men man NNS work_txjg7snw3bgwjg44gi5da2xsfm 28 12 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 28 13 all all DT work_txjg7snw3bgwjg44gi5da2xsfm 28 14 aspects aspect NNS work_txjg7snw3bgwjg44gi5da2xsfm 28 15 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 28 16 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 28 17 progression progression NN work_txjg7snw3bgwjg44gi5da2xsfm 28 18 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 28 19 localized localized JJ work_txjg7snw3bgwjg44gi5da2xsfm 28 20 melanoma melanoma NNP work_txjg7snw3bgwjg44gi5da2xsfm 28 21 , , , work_txjg7snw3bgwjg44gi5da2xsfm 28 22 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 28 23 an an DT work_txjg7snw3bgwjg44gi5da2xsfm 28 24 analysis analysis NN work_txjg7snw3bgwjg44gi5da2xsfm 28 25 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 28 26 2,672 2,672 CD work_txjg7snw3bgwjg44gi5da2xsfm 28 27 patients patient NNS work_txjg7snw3bgwjg44gi5da2xsfm 28 28 ( ( -LRB- work_txjg7snw3bgwjg44gi5da2xsfm 28 29 J J NNP work_txjg7snw3bgwjg44gi5da2xsfm 28 30 Clin Clin NNP work_txjg7snw3bgwjg44gi5da2xsfm 28 31 Oncol Oncol NNP work_txjg7snw3bgwjg44gi5da2xsfm 28 32 online online RB work_txjg7snw3bgwjg44gi5da2xsfm 28 33 ahead ahead RB work_txjg7snw3bgwjg44gi5da2xsfm 28 34 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 28 35 print print NN work_txjg7snw3bgwjg44gi5da2xsfm 28 36 2012 2012 CD work_txjg7snw3bgwjg44gi5da2xsfm 28 37 Apr Apr NNP work_txjg7snw3bgwjg44gi5da2xsfm 28 38 30 30 CD work_txjg7snw3bgwjg44gi5da2xsfm 28 39 ) ) -RRB- work_txjg7snw3bgwjg44gi5da2xsfm 28 40 . . . work_txjg7snw3bgwjg44gi5da2xsfm 29 1 • • NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 2     _SP work_txjg7snw3bgwjg44gi5da2xsfm 29 3 As as IN work_txjg7snw3bgwjg44gi5da2xsfm 29 4 Congress Congress NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 5 studies study NNS work_txjg7snw3bgwjg44gi5da2xsfm 29 6 reauthorization reauthorization NN work_txjg7snw3bgwjg44gi5da2xsfm 29 7 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 29 8 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 29 9 Pediatric Pediatric NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 10 Research Research NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 11 Equity Equity NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 12 Act Act NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 13 , , , work_txjg7snw3bgwjg44gi5da2xsfm 29 14 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 29 15 Alliance Alliance NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 16 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 29 17 Childhood Childhood NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 18 Cancer Cancer NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 19 has have VBZ work_txjg7snw3bgwjg44gi5da2xsfm 29 20 asked ask VBN work_txjg7snw3bgwjg44gi5da2xsfm 29 21 that that IN work_txjg7snw3bgwjg44gi5da2xsfm 29 22 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 29 23 revised revise VBN work_txjg7snw3bgwjg44gi5da2xsfm 29 24 bill bill NN work_txjg7snw3bgwjg44gi5da2xsfm 29 25 require require VBP work_txjg7snw3bgwjg44gi5da2xsfm 29 26 pediatric pediatric JJ work_txjg7snw3bgwjg44gi5da2xsfm 29 27 on- on- NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 28 cology cology NN work_txjg7snw3bgwjg44gi5da2xsfm 29 29 studies study NNS work_txjg7snw3bgwjg44gi5da2xsfm 29 30 when when WRB work_txjg7snw3bgwjg44gi5da2xsfm 29 31 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 29 32 relevant relevant JJ work_txjg7snw3bgwjg44gi5da2xsfm 29 33 target target NN work_txjg7snw3bgwjg44gi5da2xsfm 29 34 or or CC work_txjg7snw3bgwjg44gi5da2xsfm 29 35 pathway pathway NN work_txjg7snw3bgwjg44gi5da2xsfm 29 36 is be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 29 37 explicitly explicitly RB work_txjg7snw3bgwjg44gi5da2xsfm 29 38 included include VBN work_txjg7snw3bgwjg44gi5da2xsfm 29 39 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 29 40 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 29 41 prod- prod- NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 42 uct uct NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 43 label label NNP work_txjg7snw3bgwjg44gi5da2xsfm 29 44 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 29 45 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 29 46 new new JJ work_txjg7snw3bgwjg44gi5da2xsfm 29 47 adult adult NN work_txjg7snw3bgwjg44gi5da2xsfm 29 48 oncology oncology NN work_txjg7snw3bgwjg44gi5da2xsfm 29 49 drug drug NN work_txjg7snw3bgwjg44gi5da2xsfm 29 50 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 29 51 is be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 29 52 highly highly RB work_txjg7snw3bgwjg44gi5da2xsfm 29 53 relevant relevant JJ work_txjg7snw3bgwjg44gi5da2xsfm 29 54 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 29 55 any any DT work_txjg7snw3bgwjg44gi5da2xsfm 29 56 pediatric pediatric JJ work_txjg7snw3bgwjg44gi5da2xsfm 29 57 cancer cancer NN work_txjg7snw3bgwjg44gi5da2xsfm 29 58 . . . work_txjg7snw3bgwjg44gi5da2xsfm 30 1 • • NNP work_txjg7snw3bgwjg44gi5da2xsfm 30 2     _SP work_txjg7snw3bgwjg44gi5da2xsfm 30 3 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 30 4 European European NNP work_txjg7snw3bgwjg44gi5da2xsfm 30 5 Patent Patent NNP work_txjg7snw3bgwjg44gi5da2xsfm 30 6 Office Office NNP work_txjg7snw3bgwjg44gi5da2xsfm 30 7 has have VBZ work_txjg7snw3bgwjg44gi5da2xsfm 30 8 awarded award VBN work_txjg7snw3bgwjg44gi5da2xsfm 30 9 Rosetta Rosetta NNP work_txjg7snw3bgwjg44gi5da2xsfm 30 10 Genomics Genomics NNP work_txjg7snw3bgwjg44gi5da2xsfm 30 11 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 30 12 Philadelphia Philadelphia NNP work_txjg7snw3bgwjg44gi5da2xsfm 30 13 , , , work_txjg7snw3bgwjg44gi5da2xsfm 30 14 PA PA NNP work_txjg7snw3bgwjg44gi5da2xsfm 30 15 , , , work_txjg7snw3bgwjg44gi5da2xsfm 30 16 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 30 17 patent patent NN work_txjg7snw3bgwjg44gi5da2xsfm 30 18 covering cover VBG work_txjg7snw3bgwjg44gi5da2xsfm 30 19 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 30 20 use use NN work_txjg7snw3bgwjg44gi5da2xsfm 30 21 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 30 22 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 30 23 microRNA microRNA NNP work_txjg7snw3bgwjg44gi5da2xsfm 30 24 miR-34a mir-34a NN work_txjg7snw3bgwjg44gi5da2xsfm 30 25 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 30 26 drugs drug NNS work_txjg7snw3bgwjg44gi5da2xsfm 30 27 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 30 28 treating treat VBG work_txjg7snw3bgwjg44gi5da2xsfm 30 29 p53-nega- p53-nega- JJ work_txjg7snw3bgwjg44gi5da2xsfm 30 30 tive tive JJ work_txjg7snw3bgwjg44gi5da2xsfm 30 31 cancers cancer NNS work_txjg7snw3bgwjg44gi5da2xsfm 30 32 . . . work_txjg7snw3bgwjg44gi5da2xsfm 31 1 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 31 2 company company NN work_txjg7snw3bgwjg44gi5da2xsfm 31 3 says say VBZ work_txjg7snw3bgwjg44gi5da2xsfm 31 4 that that IN work_txjg7snw3bgwjg44gi5da2xsfm 31 5 miR- miR- NNP work_txjg7snw3bgwjg44gi5da2xsfm 31 6 34a 34a CD work_txjg7snw3bgwjg44gi5da2xsfm 31 7 is be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 31 8 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 31 9 direct direct JJ work_txjg7snw3bgwjg44gi5da2xsfm 31 10 transcriptional transcriptional JJ work_txjg7snw3bgwjg44gi5da2xsfm 31 11 target target NN work_txjg7snw3bgwjg44gi5da2xsfm 31 12 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 31 13 p53 p53 NN work_txjg7snw3bgwjg44gi5da2xsfm 31 14 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 31 15 that that DT work_txjg7snw3bgwjg44gi5da2xsfm 31 16 perturbation perturbation NN work_txjg7snw3bgwjg44gi5da2xsfm 31 17 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 31 18 miR-34a miR-34a NNS work_txjg7snw3bgwjg44gi5da2xsfm 31 19 ex- ex- DT work_txjg7snw3bgwjg44gi5da2xsfm 31 20 pression pression NN work_txjg7snw3bgwjg44gi5da2xsfm 31 21 may may MD work_txjg7snw3bgwjg44gi5da2xsfm 31 22 contribute contribute VB work_txjg7snw3bgwjg44gi5da2xsfm 31 23 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 31 24 tumorigenesis tumorigenesis NN work_txjg7snw3bgwjg44gi5da2xsfm 31 25 . . . work_txjg7snw3bgwjg44gi5da2xsfm 32 1 • • NNP work_txjg7snw3bgwjg44gi5da2xsfm 32 2     _SP work_txjg7snw3bgwjg44gi5da2xsfm 32 3 “ " `` work_txjg7snw3bgwjg44gi5da2xsfm 32 4 Investigators investigator NNS work_txjg7snw3bgwjg44gi5da2xsfm 32 5 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 32 6 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 32 7 PhD phd NN work_txjg7snw3bgwjg44gi5da2xsfm 32 8 have have VBP work_txjg7snw3bgwjg44gi5da2xsfm 32 9 a a DT work_txjg7snw3bgwjg44gi5da2xsfm 32 10 slightly slightly RB work_txjg7snw3bgwjg44gi5da2xsfm 32 11 lower low JJR work_txjg7snw3bgwjg44gi5da2xsfm 32 12 [ [ -LRB- work_txjg7snw3bgwjg44gi5da2xsfm 32 13 NIH NIH NNP work_txjg7snw3bgwjg44gi5da2xsfm 32 14 ] ] -RRB- work_txjg7snw3bgwjg44gi5da2xsfm 32 15 funding funding NN work_txjg7snw3bgwjg44gi5da2xsfm 32 16 rate rate NN work_txjg7snw3bgwjg44gi5da2xsfm 32 17 than than IN work_txjg7snw3bgwjg44gi5da2xsfm 32 18 those those DT work_txjg7snw3bgwjg44gi5da2xsfm 32 19 with with IN work_txjg7snw3bgwjg44gi5da2xsfm 32 20 medical medical JJ work_txjg7snw3bgwjg44gi5da2xsfm 32 21 degrees degree NNS work_txjg7snw3bgwjg44gi5da2xsfm 32 22 , , , work_txjg7snw3bgwjg44gi5da2xsfm 32 23 ” " '' work_txjg7snw3bgwjg44gi5da2xsfm 32 24 noted note VBD work_txjg7snw3bgwjg44gi5da2xsfm 32 25 Sally Sally NNP work_txjg7snw3bgwjg44gi5da2xsfm 32 26 Rockey Rockey NNP work_txjg7snw3bgwjg44gi5da2xsfm 32 27 , , , work_txjg7snw3bgwjg44gi5da2xsfm 32 28 PhD phd NN work_txjg7snw3bgwjg44gi5da2xsfm 32 29 , , , work_txjg7snw3bgwjg44gi5da2xsfm 32 30 NIH NIH NNP work_txjg7snw3bgwjg44gi5da2xsfm 32 31 ’s ’s NNP work_txjg7snw3bgwjg44gi5da2xsfm 32 32 Deputy Deputy NNP work_txjg7snw3bgwjg44gi5da2xsfm 32 33 Director Director NNP work_txjg7snw3bgwjg44gi5da2xsfm 32 34 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 32 35 Extramural Extramural NNP work_txjg7snw3bgwjg44gi5da2xsfm 32 36 Research Research NNP work_txjg7snw3bgwjg44gi5da2xsfm 32 37 . . . work_txjg7snw3bgwjg44gi5da2xsfm 33 1 “ " `` work_txjg7snw3bgwjg44gi5da2xsfm 33 2 To to TO work_txjg7snw3bgwjg44gi5da2xsfm 33 3 keep keep VB work_txjg7snw3bgwjg44gi5da2xsfm 33 4 these these DT work_txjg7snw3bgwjg44gi5da2xsfm 33 5 data datum NNS work_txjg7snw3bgwjg44gi5da2xsfm 33 6 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 33 7 context context NN work_txjg7snw3bgwjg44gi5da2xsfm 33 8 , , , work_txjg7snw3bgwjg44gi5da2xsfm 33 9 remember remember VB work_txjg7snw3bgwjg44gi5da2xsfm 33 10 that that IN work_txjg7snw3bgwjg44gi5da2xsfm 33 11 about about RB work_txjg7snw3bgwjg44gi5da2xsfm 33 12 30 30 CD work_txjg7snw3bgwjg44gi5da2xsfm 33 13 % % NN work_txjg7snw3bgwjg44gi5da2xsfm 33 14 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 33 15 principal principal JJ work_txjg7snw3bgwjg44gi5da2xsfm 33 16 in- in- JJ work_txjg7snw3bgwjg44gi5da2xsfm 33 17 vestigators vestigator NNS work_txjg7snw3bgwjg44gi5da2xsfm 33 18 hold hold VBP work_txjg7snw3bgwjg44gi5da2xsfm 33 19 MDs md NNS work_txjg7snw3bgwjg44gi5da2xsfm 33 20 or or CC work_txjg7snw3bgwjg44gi5da2xsfm 33 21 MD MD NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 22 / / SYM work_txjg7snw3bgwjg44gi5da2xsfm 33 23 PhDs PhDs NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 24 . . . work_txjg7snw3bgwjg44gi5da2xsfm 33 25 ” " '' work_txjg7snw3bgwjg44gi5da2xsfm 33 26 • • NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 27     _SP work_txjg7snw3bgwjg44gi5da2xsfm 33 28 Turning turn VBG work_txjg7snw3bgwjg44gi5da2xsfm 33 29 data datum NNS work_txjg7snw3bgwjg44gi5da2xsfm 33 30 from from IN work_txjg7snw3bgwjg44gi5da2xsfm 33 31 cancer cancer NN work_txjg7snw3bgwjg44gi5da2xsfm 33 32 research research NN work_txjg7snw3bgwjg44gi5da2xsfm 33 33 into into IN work_txjg7snw3bgwjg44gi5da2xsfm 33 34 discoveries discovery NNS work_txjg7snw3bgwjg44gi5da2xsfm 33 35 will will MD work_txjg7snw3bgwjg44gi5da2xsfm 33 36 require require VB work_txjg7snw3bgwjg44gi5da2xsfm 33 37 fundamental fundamental JJ work_txjg7snw3bgwjg44gi5da2xsfm 33 38 changes change NNS work_txjg7snw3bgwjg44gi5da2xsfm 33 39 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 33 40 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 33 41 way way NN work_txjg7snw3bgwjg44gi5da2xsfm 33 42 researchers researcher NNS work_txjg7snw3bgwjg44gi5da2xsfm 33 43 share share VBP work_txjg7snw3bgwjg44gi5da2xsfm 33 44 data datum NNS work_txjg7snw3bgwjg44gi5da2xsfm 33 45 , , , work_txjg7snw3bgwjg44gi5da2xsfm 33 46 access access NN work_txjg7snw3bgwjg44gi5da2xsfm 33 47 patient patient NN work_txjg7snw3bgwjg44gi5da2xsfm 33 48 samples sample NNS work_txjg7snw3bgwjg44gi5da2xsfm 33 49 , , , work_txjg7snw3bgwjg44gi5da2xsfm 33 50 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 33 51 gather gather VB work_txjg7snw3bgwjg44gi5da2xsfm 33 52 informed informed JJ work_txjg7snw3bgwjg44gi5da2xsfm 33 53 consent consent NN work_txjg7snw3bgwjg44gi5da2xsfm 33 54 , , , work_txjg7snw3bgwjg44gi5da2xsfm 33 55 remarked remark VBD work_txjg7snw3bgwjg44gi5da2xsfm 33 56 John John NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 57 Quackenbush Quackenbush NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 58 , , , work_txjg7snw3bgwjg44gi5da2xsfm 33 59 PhD phd NN work_txjg7snw3bgwjg44gi5da2xsfm 33 60 , , , work_txjg7snw3bgwjg44gi5da2xsfm 33 61 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 33 62 Dana Dana NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 63 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 33 64 Farber Farber NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 65 Cancer Cancer NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 66 Institute Institute NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 67 at at IN work_txjg7snw3bgwjg44gi5da2xsfm 33 68 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 33 69 Bio Bio NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 70 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 33 71 IT IT NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 72 World World NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 73 Conference Conference NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 74 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 33 75 Expo Expo NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 76 2012 2012 CD work_txjg7snw3bgwjg44gi5da2xsfm 33 77 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 33 78 Boston Boston NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 79 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 33 80 April April NNP work_txjg7snw3bgwjg44gi5da2xsfm 33 81 . . . work_txjg7snw3bgwjg44gi5da2xsfm 34 1 “ " `` work_txjg7snw3bgwjg44gi5da2xsfm 34 2 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 34 3 biggest big JJS work_txjg7snw3bgwjg44gi5da2xsfm 34 4 barriers barrier NNS work_txjg7snw3bgwjg44gi5da2xsfm 34 5 are be VBP work_txjg7snw3bgwjg44gi5da2xsfm 34 6 not not RB work_txjg7snw3bgwjg44gi5da2xsfm 34 7 tech- tech- RB work_txjg7snw3bgwjg44gi5da2xsfm 34 8 nical nical JJ work_txjg7snw3bgwjg44gi5da2xsfm 34 9 or or CC work_txjg7snw3bgwjg44gi5da2xsfm 34 10 intellectual intellectual JJ work_txjg7snw3bgwjg44gi5da2xsfm 34 11 ; ; : work_txjg7snw3bgwjg44gi5da2xsfm 34 12 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 34 13 biggest big JJS work_txjg7snw3bgwjg44gi5da2xsfm 34 14 barri- barri- JJ work_txjg7snw3bgwjg44gi5da2xsfm 34 15 ers er NNS work_txjg7snw3bgwjg44gi5da2xsfm 34 16 are be VBP work_txjg7snw3bgwjg44gi5da2xsfm 34 17 cultural cultural JJ work_txjg7snw3bgwjg44gi5da2xsfm 34 18 , , , work_txjg7snw3bgwjg44gi5da2xsfm 34 19 ” " '' work_txjg7snw3bgwjg44gi5da2xsfm 34 20 said say VBD work_txjg7snw3bgwjg44gi5da2xsfm 34 21 Quackenbush Quackenbush NNP work_txjg7snw3bgwjg44gi5da2xsfm 34 22 . . . work_txjg7snw3bgwjg44gi5da2xsfm 35 1 NOTED NOTED NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 2 Grant Grant NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 3 Success Success NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 4 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 35 5 New New NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 6 Investigators Investigators NNPS work_txjg7snw3bgwjg44gi5da2xsfm 35 7 0 0 CD work_txjg7snw3bgwjg44gi5da2xsfm 35 8 % % NN work_txjg7snw3bgwjg44gi5da2xsfm 35 9 RO1 RO1 NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 10 R21 R21 NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 11 3 3 CD work_txjg7snw3bgwjg44gi5da2xsfm 35 12 % % NN work_txjg7snw3bgwjg44gi5da2xsfm 35 13 6 6 CD work_txjg7snw3bgwjg44gi5da2xsfm 35 14 % % NN work_txjg7snw3bgwjg44gi5da2xsfm 35 15 9 9 CD work_txjg7snw3bgwjg44gi5da2xsfm 35 16 % % NN work_txjg7snw3bgwjg44gi5da2xsfm 35 17 12 12 CD work_txjg7snw3bgwjg44gi5da2xsfm 35 18 % % NN work_txjg7snw3bgwjg44gi5da2xsfm 35 19 15 15 CD work_txjg7snw3bgwjg44gi5da2xsfm 35 20 % % NN work_txjg7snw3bgwjg44gi5da2xsfm 35 21 National National NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 22 Cancer Cancer NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 23 Institute Institute NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 24 funding funding NN work_txjg7snw3bgwjg44gi5da2xsfm 35 25 approval approval NN work_txjg7snw3bgwjg44gi5da2xsfm 35 26 rates rate NNS work_txjg7snw3bgwjg44gi5da2xsfm 35 27 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 35 28 applications application NNS work_txjg7snw3bgwjg44gi5da2xsfm 35 29 during during IN work_txjg7snw3bgwjg44gi5da2xsfm 35 30 fi fi IN work_txjg7snw3bgwjg44gi5da2xsfm 35 31 scal scal JJ work_txjg7snw3bgwjg44gi5da2xsfm 35 32 year year NN work_txjg7snw3bgwjg44gi5da2xsfm 35 33 2011 2011 CD work_txjg7snw3bgwjg44gi5da2xsfm 35 34 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 35 35 RO1 RO1 NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 36 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 35 37 R21 R21 NNP work_txjg7snw3bgwjg44gi5da2xsfm 35 38 grants grant NNS work_txjg7snw3bgwjg44gi5da2xsfm 35 39 . . . work_txjg7snw3bgwjg44gi5da2xsfm 36 1 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 36 2 R21 R21 NNP work_txjg7snw3bgwjg44gi5da2xsfm 36 3 exploratory exploratory NN work_txjg7snw3bgwjg44gi5da2xsfm 36 4 / / SYM work_txjg7snw3bgwjg44gi5da2xsfm 36 5 developmental developmental JJ work_txjg7snw3bgwjg44gi5da2xsfm 36 6 research research NN work_txjg7snw3bgwjg44gi5da2xsfm 36 7 grants grant NNS work_txjg7snw3bgwjg44gi5da2xsfm 36 8 are be VBP work_txjg7snw3bgwjg44gi5da2xsfm 36 9 limited limit VBN work_txjg7snw3bgwjg44gi5da2xsfm 36 10 up up IN work_txjg7snw3bgwjg44gi5da2xsfm 36 11 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 36 12 2 2 CD work_txjg7snw3bgwjg44gi5da2xsfm 36 13 years year NNS work_txjg7snw3bgwjg44gi5da2xsfm 36 14 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 36 15 typically typically RB work_txjg7snw3bgwjg44gi5da2xsfm 36 16 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 36 17 $ $ $ work_txjg7snw3bgwjg44gi5da2xsfm 36 18 275,000 275,000 CD work_txjg7snw3bgwjg44gi5da2xsfm 36 19 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 36 20 direct direct JJ work_txjg7snw3bgwjg44gi5da2xsfm 36 21 costs cost NNS work_txjg7snw3bgwjg44gi5da2xsfm 36 22 . . . work_txjg7snw3bgwjg44gi5da2xsfm 37 1 The the DT work_txjg7snw3bgwjg44gi5da2xsfm 37 2 striking striking JJ work_txjg7snw3bgwjg44gi5da2xsfm 37 3 difference difference NN work_txjg7snw3bgwjg44gi5da2xsfm 37 4 in in IN work_txjg7snw3bgwjg44gi5da2xsfm 37 5 success success NN work_txjg7snw3bgwjg44gi5da2xsfm 37 6 rates rate NNS work_txjg7snw3bgwjg44gi5da2xsfm 37 7 is be VBZ work_txjg7snw3bgwjg44gi5da2xsfm 37 8 because because IN work_txjg7snw3bgwjg44gi5da2xsfm 37 9 these these DT work_txjg7snw3bgwjg44gi5da2xsfm 37 10 investigators investigator NNS work_txjg7snw3bgwjg44gi5da2xsfm 37 11 are be VBP work_txjg7snw3bgwjg44gi5da2xsfm 37 12 given give VBN work_txjg7snw3bgwjg44gi5da2xsfm 37 13 preferential preferential JJ work_txjg7snw3bgwjg44gi5da2xsfm 37 14 consideration consideration NN work_txjg7snw3bgwjg44gi5da2xsfm 37 15 over over IN work_txjg7snw3bgwjg44gi5da2xsfm 37 16 existing exist VBG work_txjg7snw3bgwjg44gi5da2xsfm 37 17 investigators investigator NNS work_txjg7snw3bgwjg44gi5da2xsfm 37 18 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 37 19 RO1s RO1s NNP work_txjg7snw3bgwjg44gi5da2xsfm 37 20 , , , work_txjg7snw3bgwjg44gi5da2xsfm 37 21 NCI NCI NNP work_txjg7snw3bgwjg44gi5da2xsfm 37 22 says say VBZ work_txjg7snw3bgwjg44gi5da2xsfm 37 23 . . . work_txjg7snw3bgwjg44gi5da2xsfm 38 1 CD-11-FM.indd CD-11-FM.indd NNP work_txjg7snw3bgwjg44gi5da2xsfm 38 2 477CD-11-FM.indd 477cd-11-fm.indd CD work_txjg7snw3bgwjg44gi5da2xsfm 38 3 477 477 CD work_txjg7snw3bgwjg44gi5da2xsfm 38 4 22/05/12 22/05/12 CD work_txjg7snw3bgwjg44gi5da2xsfm 38 5 5:37 5:37 CD work_txjg7snw3bgwjg44gi5da2xsfm 38 6 PM22/05/12 PM22/05/12 NNP work_txjg7snw3bgwjg44gi5da2xsfm 38 7 5:37 5:37 CD work_txjg7snw3bgwjg44gi5da2xsfm 38 8 PMon PMon NNP work_txjg7snw3bgwjg44gi5da2xsfm 38 9 April April NNP work_txjg7snw3bgwjg44gi5da2xsfm 38 10 5 5 CD work_txjg7snw3bgwjg44gi5da2xsfm 38 11 , , , work_txjg7snw3bgwjg44gi5da2xsfm 38 12 2021 2021 CD work_txjg7snw3bgwjg44gi5da2xsfm 38 13 . . . work_txjg7snw3bgwjg44gi5da2xsfm 39 1 © © LS work_txjg7snw3bgwjg44gi5da2xsfm 39 2 2012 2012 CD work_txjg7snw3bgwjg44gi5da2xsfm 39 3 American American NNP work_txjg7snw3bgwjg44gi5da2xsfm 39 4 Association Association NNP work_txjg7snw3bgwjg44gi5da2xsfm 39 5 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 39 6 Cancer Cancer NNP work_txjg7snw3bgwjg44gi5da2xsfm 39 7 Research Research NNP work_txjg7snw3bgwjg44gi5da2xsfm 39 8 . . . work_txjg7snw3bgwjg44gi5da2xsfm 40 1 cancerdiscovery.aacrjournals.org cancerdiscovery.aacrjournals.org NNP work_txjg7snw3bgwjg44gi5da2xsfm 40 2 Downloaded Downloaded NNP work_txjg7snw3bgwjg44gi5da2xsfm 40 3 from from IN work_txjg7snw3bgwjg44gi5da2xsfm 40 4 Published publish VBN work_txjg7snw3bgwjg44gi5da2xsfm 40 5 OnlineFirst OnlineFirst NNP work_txjg7snw3bgwjg44gi5da2xsfm 40 6 April April NNP work_txjg7snw3bgwjg44gi5da2xsfm 40 7 19 19 CD work_txjg7snw3bgwjg44gi5da2xsfm 40 8 , , , work_txjg7snw3bgwjg44gi5da2xsfm 40 9 2012 2012 CD work_txjg7snw3bgwjg44gi5da2xsfm 40 10 ; ; : work_txjg7snw3bgwjg44gi5da2xsfm 40 11 DOI DOI NNP work_txjg7snw3bgwjg44gi5da2xsfm 40 12 : : : work_txjg7snw3bgwjg44gi5da2xsfm 40 13 10.1158/2159 10.1158/2159 CD work_txjg7snw3bgwjg44gi5da2xsfm 40 14 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 40 15 8290.CD 8290.cd CD work_txjg7snw3bgwjg44gi5da2xsfm 40 16 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 40 17 NB2012 NB2012 NNP work_txjg7snw3bgwjg44gi5da2xsfm 40 18 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 40 19 039 039 CD work_txjg7snw3bgwjg44gi5da2xsfm 40 20 http://cancerdiscovery.aacrjournals.org/ http://cancerdiscovery.aacrjournals.org/ NN work_txjg7snw3bgwjg44gi5da2xsfm 40 21 2012;2:477 2012;2:477 CD work_txjg7snw3bgwjg44gi5da2xsfm 40 22 . . . work_txjg7snw3bgwjg44gi5da2xsfm 41 1 Published publish VBN work_txjg7snw3bgwjg44gi5da2xsfm 41 2 OnlineFirst OnlineFirst NNP work_txjg7snw3bgwjg44gi5da2xsfm 41 3 April April NNP work_txjg7snw3bgwjg44gi5da2xsfm 41 4 19 19 CD work_txjg7snw3bgwjg44gi5da2xsfm 41 5 , , , work_txjg7snw3bgwjg44gi5da2xsfm 41 6 2012.Cancer 2012.cancer CD work_txjg7snw3bgwjg44gi5da2xsfm 41 7 Discovery Discovery NNP work_txjg7snw3bgwjg44gi5da2xsfm 41 8 BEAUTY BEAUTY VBD work_txjg7snw3bgwjg44gi5da2xsfm 41 9 Combines Combines NNP work_txjg7snw3bgwjg44gi5da2xsfm 41 10 Sequencing Sequencing NNP work_txjg7snw3bgwjg44gi5da2xsfm 41 11 , , , work_txjg7snw3bgwjg44gi5da2xsfm 41 12 Avatars Avatars NNP work_txjg7snw3bgwjg44gi5da2xsfm 41 13 Updated update VBN work_txjg7snw3bgwjg44gi5da2xsfm 41 14 version version NN work_txjg7snw3bgwjg44gi5da2xsfm 41 15 10.1158/2159 10.1158/2159 CD work_txjg7snw3bgwjg44gi5da2xsfm 41 16 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 41 17 8290.CD 8290.cd CD work_txjg7snw3bgwjg44gi5da2xsfm 41 18 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 41 19 NB2012 NB2012 NNP work_txjg7snw3bgwjg44gi5da2xsfm 41 20 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 41 21 039doi 039doi NNP work_txjg7snw3bgwjg44gi5da2xsfm 41 22 : : : work_txjg7snw3bgwjg44gi5da2xsfm 41 23 Access access VB work_txjg7snw3bgwjg44gi5da2xsfm 41 24 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 41 25 most most RBS work_txjg7snw3bgwjg44gi5da2xsfm 41 26 recent recent JJ work_txjg7snw3bgwjg44gi5da2xsfm 41 27 version version NN work_txjg7snw3bgwjg44gi5da2xsfm 41 28 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 41 29 this this DT work_txjg7snw3bgwjg44gi5da2xsfm 41 30 article article NN work_txjg7snw3bgwjg44gi5da2xsfm 41 31 at at IN work_txjg7snw3bgwjg44gi5da2xsfm 41 32 : : : work_txjg7snw3bgwjg44gi5da2xsfm 41 33 E e NN work_txjg7snw3bgwjg44gi5da2xsfm 41 34 - - NN work_txjg7snw3bgwjg44gi5da2xsfm 41 35 mail mail NN work_txjg7snw3bgwjg44gi5da2xsfm 41 36 alerts alert NNS work_txjg7snw3bgwjg44gi5da2xsfm 41 37 related relate VBN work_txjg7snw3bgwjg44gi5da2xsfm 41 38 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 41 39 this this DT work_txjg7snw3bgwjg44gi5da2xsfm 41 40 article article NN work_txjg7snw3bgwjg44gi5da2xsfm 41 41 or or CC work_txjg7snw3bgwjg44gi5da2xsfm 41 42 journal journal NN work_txjg7snw3bgwjg44gi5da2xsfm 41 43 . . . work_txjg7snw3bgwjg44gi5da2xsfm 41 44 Sign sign VB work_txjg7snw3bgwjg44gi5da2xsfm 41 45 up up RP work_txjg7snw3bgwjg44gi5da2xsfm 41 46 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 41 47 receive receive VB work_txjg7snw3bgwjg44gi5da2xsfm 41 48 free free JJ work_txjg7snw3bgwjg44gi5da2xsfm 41 49 email email NN work_txjg7snw3bgwjg44gi5da2xsfm 41 50 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 41 51 alerts alert NNS work_txjg7snw3bgwjg44gi5da2xsfm 41 52 Subscriptions Subscriptions NNPS work_txjg7snw3bgwjg44gi5da2xsfm 41 53 Reprints Reprints NNPS work_txjg7snw3bgwjg44gi5da2xsfm 41 54 and and CC work_txjg7snw3bgwjg44gi5da2xsfm 41 55 .pubs@aacr.org .pubs@aacr.org . work_txjg7snw3bgwjg44gi5da2xsfm 41 56 To to TO work_txjg7snw3bgwjg44gi5da2xsfm 41 57 order order VB work_txjg7snw3bgwjg44gi5da2xsfm 41 58 reprints reprint NNS work_txjg7snw3bgwjg44gi5da2xsfm 41 59 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 41 60 this this DT work_txjg7snw3bgwjg44gi5da2xsfm 41 61 article article NN work_txjg7snw3bgwjg44gi5da2xsfm 41 62 or or CC work_txjg7snw3bgwjg44gi5da2xsfm 41 63 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 41 64 subscribe subscribe VB work_txjg7snw3bgwjg44gi5da2xsfm 41 65 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 41 66 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 41 67 journal journal NN work_txjg7snw3bgwjg44gi5da2xsfm 41 68 , , , work_txjg7snw3bgwjg44gi5da2xsfm 41 69 contact contact VB work_txjg7snw3bgwjg44gi5da2xsfm 41 70 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 41 71 AACR AACR NNP work_txjg7snw3bgwjg44gi5da2xsfm 41 72 Publications Publications NNPS work_txjg7snw3bgwjg44gi5da2xsfm 41 73 Department Department NNP work_txjg7snw3bgwjg44gi5da2xsfm 41 74 at at IN work_txjg7snw3bgwjg44gi5da2xsfm 41 75 Permissions Permissions NNPS work_txjg7snw3bgwjg44gi5da2xsfm 41 76 Rightslink rightslink VBP work_txjg7snw3bgwjg44gi5da2xsfm 41 77 site site NN work_txjg7snw3bgwjg44gi5da2xsfm 41 78 . . . work_txjg7snw3bgwjg44gi5da2xsfm 42 1 Click click VB work_txjg7snw3bgwjg44gi5da2xsfm 42 2 on on IN work_txjg7snw3bgwjg44gi5da2xsfm 42 3 " " `` work_txjg7snw3bgwjg44gi5da2xsfm 42 4 Request Request NNP work_txjg7snw3bgwjg44gi5da2xsfm 42 5 Permissions permission NNS work_txjg7snw3bgwjg44gi5da2xsfm 42 6 " " '' work_txjg7snw3bgwjg44gi5da2xsfm 42 7 which which WDT work_txjg7snw3bgwjg44gi5da2xsfm 42 8 will will MD work_txjg7snw3bgwjg44gi5da2xsfm 42 9 take take VB work_txjg7snw3bgwjg44gi5da2xsfm 42 10 you -PRON- PRP work_txjg7snw3bgwjg44gi5da2xsfm 42 11 to to IN work_txjg7snw3bgwjg44gi5da2xsfm 42 12 the the DT work_txjg7snw3bgwjg44gi5da2xsfm 42 13 Copyright Copyright NNP work_txjg7snw3bgwjg44gi5da2xsfm 42 14 Clearance Clearance NNP work_txjg7snw3bgwjg44gi5da2xsfm 42 15 Center Center NNP work_txjg7snw3bgwjg44gi5da2xsfm 42 16 's 's POS work_txjg7snw3bgwjg44gi5da2xsfm 42 17 ( ( -LRB- work_txjg7snw3bgwjg44gi5da2xsfm 42 18 CCC CCC NNP work_txjg7snw3bgwjg44gi5da2xsfm 42 19 ) ) -RRB- work_txjg7snw3bgwjg44gi5da2xsfm 42 20 .http://cancerdiscovery.aacrjournals.org/content/2/6/477.1 .http://cancerdiscovery.aacrjournals.org/content/2/6/477.1 . work_txjg7snw3bgwjg44gi5da2xsfm 42 21 To to TO work_txjg7snw3bgwjg44gi5da2xsfm 42 22 request request VB work_txjg7snw3bgwjg44gi5da2xsfm 42 23 permission permission NN work_txjg7snw3bgwjg44gi5da2xsfm 42 24 to to TO work_txjg7snw3bgwjg44gi5da2xsfm 42 25 re re VB work_txjg7snw3bgwjg44gi5da2xsfm 42 26 - - VB work_txjg7snw3bgwjg44gi5da2xsfm 42 27 use use VB work_txjg7snw3bgwjg44gi5da2xsfm 42 28 all all DT work_txjg7snw3bgwjg44gi5da2xsfm 42 29 or or CC work_txjg7snw3bgwjg44gi5da2xsfm 42 30 part part NN work_txjg7snw3bgwjg44gi5da2xsfm 42 31 of of IN work_txjg7snw3bgwjg44gi5da2xsfm 42 32 this this DT work_txjg7snw3bgwjg44gi5da2xsfm 42 33 article article NN work_txjg7snw3bgwjg44gi5da2xsfm 42 34 , , , work_txjg7snw3bgwjg44gi5da2xsfm 42 35 use use VB work_txjg7snw3bgwjg44gi5da2xsfm 42 36 this this DT work_txjg7snw3bgwjg44gi5da2xsfm 42 37 link link NN work_txjg7snw3bgwjg44gi5da2xsfm 42 38 on on IN work_txjg7snw3bgwjg44gi5da2xsfm 42 39 April April NNP work_txjg7snw3bgwjg44gi5da2xsfm 42 40 5 5 CD work_txjg7snw3bgwjg44gi5da2xsfm 42 41 , , , work_txjg7snw3bgwjg44gi5da2xsfm 42 42 2021 2021 CD work_txjg7snw3bgwjg44gi5da2xsfm 42 43 . . . work_txjg7snw3bgwjg44gi5da2xsfm 43 1 © © LS work_txjg7snw3bgwjg44gi5da2xsfm 43 2 2012 2012 CD work_txjg7snw3bgwjg44gi5da2xsfm 43 3 American American NNP work_txjg7snw3bgwjg44gi5da2xsfm 43 4 Association Association NNP work_txjg7snw3bgwjg44gi5da2xsfm 43 5 for for IN work_txjg7snw3bgwjg44gi5da2xsfm 43 6 Cancer Cancer NNP work_txjg7snw3bgwjg44gi5da2xsfm 43 7 Research Research NNP work_txjg7snw3bgwjg44gi5da2xsfm 43 8 . . . work_txjg7snw3bgwjg44gi5da2xsfm 44 1 cancerdiscovery.aacrjournals.org cancerdiscovery.aacrjournals.org NNP work_txjg7snw3bgwjg44gi5da2xsfm 44 2 Downloaded Downloaded NNP work_txjg7snw3bgwjg44gi5da2xsfm 44 3 from from IN work_txjg7snw3bgwjg44gi5da2xsfm 44 4 Published publish VBN work_txjg7snw3bgwjg44gi5da2xsfm 44 5 OnlineFirst OnlineFirst NNP work_txjg7snw3bgwjg44gi5da2xsfm 44 6 April April NNP work_txjg7snw3bgwjg44gi5da2xsfm 44 7 19 19 CD work_txjg7snw3bgwjg44gi5da2xsfm 44 8 , , , work_txjg7snw3bgwjg44gi5da2xsfm 44 9 2012 2012 CD work_txjg7snw3bgwjg44gi5da2xsfm 44 10 ; ; : work_txjg7snw3bgwjg44gi5da2xsfm 44 11 DOI DOI NNP work_txjg7snw3bgwjg44gi5da2xsfm 44 12 : : : work_txjg7snw3bgwjg44gi5da2xsfm 44 13 10.1158/2159 10.1158/2159 CD work_txjg7snw3bgwjg44gi5da2xsfm 44 14 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 44 15 8290.CD 8290.cd CD work_txjg7snw3bgwjg44gi5da2xsfm 44 16 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 44 17 NB2012 NB2012 NNP work_txjg7snw3bgwjg44gi5da2xsfm 44 18 - - HYPH work_txjg7snw3bgwjg44gi5da2xsfm 44 19 039 039 CD work_txjg7snw3bgwjg44gi5da2xsfm 44 20 http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-NB2012-039 http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.cd-nb2012-039 UH work_txjg7snw3bgwjg44gi5da2xsfm 44 21 http://cancerdiscovery.aacrjournals.org/cgi/alerts http://cancerdiscovery.aacrjournals.org/cgi/alerts CD work_txjg7snw3bgwjg44gi5da2xsfm 44 22 mailto:pubs@aacr.org mailto:pubs@aacr.org NN work_txjg7snw3bgwjg44gi5da2xsfm 44 23 http://cancerdiscovery.aacrjournals.org/content/2/6/477.1 http://cancerdiscovery.aacrjournals.org/content/2/6/477.1 NNP work_txjg7snw3bgwjg44gi5da2xsfm 44 24 http://cancerdiscovery.aacrjournals.org/ http://cancerdiscovery.aacrjournals.org/ ADD